Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.
Sign up to receive Sarepta Therapeutics’ e-mail alerts.
Click here to subscribe.
NEUGENE Antisense Compounds Show Efficacy Against Influenza A in Mice PORTLAND, Ore.--(BUSINESS WIRE)--May 1, 2007--AVI BioPharma, Inc. (Nasdaq:AVII) and collaborators presented pre-clinical data demonstrating effectiveness of NEUGENE(R) antisense compounds against seasonal influenza A virus in
PORTLAND, Ore., Apr 20, 2007 (BUSINESS WIRE) -- Fourth graph, second complete sentence should read: AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. (sted: AVI's lead NEUGENE antisense compound is designed to target cell
Jack L. Bowman named chairman; K. Michael Forrest named interim CEO PORTLAND, Ore.--(BUSINESS WIRE)--March 28, 2007--AVI BioPharma, Inc. (Nasdaq:AVII) today announced the resignation of Denis R. Burger, Ph.D., from his positions as chairman, chief executive officer and board member, effective
Moderator: Jody Cain March 15, 2007, 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2006 Fourth Quarter Financial Results conference call. At this time, all participants are in a listen–only mode. Following management’s prepared remarks, we’ll hold a Q&A session.
PORTLAND, Ore.--(BUSINESS WIRE)--March 15, 2007--AVI BioPharma, Inc. (NASDAQ:AVII) today reported financial results for the three and 12 months ended December 31, 2006. The net loss for the fourth quarter of 2006 was $8.3 million, or $0.16 per share, compared with a net loss for the fourth quarter
PORTLAND, Ore.--(BUSINESS WIRE)--March 13, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), announced that Chief Executive Officer Denis R. Burger, Ph.D., will be presenting an update on the company's business strategy and clinical development today at Cowen and Company LLC's 27th Annual Health Care
PORTLAND, Ore.--(BUSINESS WIRE)--March 8, 2007--AVI BioPharma Inc. (Nasdaq: AVII) today announced that the company will hold a conference call to discuss its 2006 fourth quarter and year end financial results on Thursday, March 15, 2007, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
Cell-Culture Research Targets HIV-1 Vif and Tar Stem Loop PORTLAND, Ore.--(BUSINESS WIRE)--March 1, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), presented research results titled "Morpholino Antisense Oligomers that Target the Lentiviral Vif Gene and Tar Stem Loop are Novel Antiretroviral Drug
PORTLAND, Ore. & OMAHA, Neb.--(BUSINESS WIRE)--Jan. 9, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), and Eleos Inc. announced today a cross-license agreement for the development of antisense drugs targeting p53, a well-studied human protein that controls cellular response to genetic damage.
PORTLAND, Ore. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), and Ercole Biotech, Inc., announced today a cross-license and collaboration agreement to identify and develop drugs that direct the splicing of messenger RNA (mRNA) to treat a variety
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.